Logo image
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
Journal article   Open access

Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer

Bin Qiu, Kaican Cai, Chun Chen, Jun Chen, Ke-Neng Chen, Qi-Xun Chen, Chao Cheng, Tian-Yang Dai, Junqiang Fan, Zhaohui Fan, …
Translational lung cancer research, Vol.10(9), pp.3713-3736
09/01/2021
DOI: 10.21037/tlcr-21-634
PMCID: PMC8512472
PMID: 34733623
url
https://doi.org/10.21037/tlcr-21-634View
Published (Version of record) Open Access

Abstract

The treatment of lung cancer is one of the major challenges in the field of oncology. According to statistics from the National Cancer Center of China in 2015, lung cancer has the highest incidence and mortality, with 733,300 new cases and 610,200 deaths across the country (1). About 85% of lung cancers are non-small cell lung cancer (NSCLC), of which 30% to 40% are considered resectable tumors, including most stage I-II and a small portion of stage IIIA tumors (2). Very early-stage NSCLC (IA) can be cured by surgery. However, more than 50% of NSCLC patients who undergo surgical treatment will relapse or metastasize within 5 years. Even if there is no lymph node metastasis and the primary
Oncology Respiratory System Life Sciences & Biomedicine Science & Technology

Details

Metrics

Logo image